Clinical Observation of Fludarabine、 Intermediate-dose Ara-C and G-CSF in Treatment for Refractory or Relapsed Acute Myeloid Leukemia(26 Cases)

VernacularTitle:FLAG方案治疗难治或复发急性髓系白血病26例临床观察
Author: Hailin DONG ; Changjian YANG ; Xiaoliang CHEN
Publication Type:Journal Article
Keywords: Leukemia,myeloid; Fludarabine; Cytarabine; Granulocyte colony-stimulating factor; Treatment outcome
From: Chinese Journal of Primary Medicine and Pharmacy 2010;17(15):2050-2052
CountryChina
Language:Chinese
Abstract: Objective To observe the therapeutic effects and side effects of FLAG regimen(fludarabine, Ara-C, and granulocyte-colony stimulating factor( C-CSF) for refractory or relapsed acute myeloid leukemia( AML). Methods Twenty-six AML were treated with fludarabine plus intermediate-dose Ara-C and G-CSF,of whom 15 cases belonged to refractory and 11 cases belonged to relapsed. Results After two courses of treatment, 14 cases were completely relieved (53. 8% ) and 5 cases were partially relieved (19.2% ). The overall effective rates was 73.1%. The main side effects were severe myelosuppression and non-hematological toxicity was mild. Conclusion FLAG regimen was very effective for refractory or relapsed acute myeloid leukemia and was well tolerated. The treatment-related mortality rate was low,so it provided a treatment choice for these patients.